The Synthetic Coumarin (CAS 91-64-5) market outlook is moderately attractive, anchored by a 6‑7% CAGR driven largely by expanding flavor‑and‑fragrance formulations and niche pharmaceutical uses. Competitive intensity is high; a handful of integrated chemical groups dominate upstream production while a growing cohort of specialty firms vie for premium, high‑purity grades, creating a dual‑layer rivalry. Over the next five to ten years, demand is expected to outpace supply modestly as end‑user capacity expands faster than current plant additions, preserving a slight deficit that supports price stability. Innovation is focused on greener synthesis routes, enzymatic catalysis, and derivative development for enhanced bioactivity, positioning early adopters for differentiation. The supply chain remains resilient, but reliance on a few large reactors introduces concentration risk, and regulatory scrutiny of residual solvents could tighten compliance costs. Key risks include raw‑material price volatility, tightening environmental regulations, and potential substitution by bio‑derived coumarin analogues. Geographically, emerging markets in Asia‑Pacific present the strongest upside, driven by rising disposable incomes and liberalized food‑additive policies.